LDL heterogeneity revisited: Lesson for the metabolic syndrome from a new interpopulation study?

European Journal of Clinical Investigation

Volumn 34, Issue 11, 2004, Pages 719-722

  Chan, D C ^a,b   Watts, Gerald F ^a,b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

LOW DENSITY LIPOPROTEIN;

BODY MASS; CARDIOVASCULAR DISEASE; GENETIC HETEROGENEITY; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; METABOLIC SYNDROME X; NOTE; POPULATION RESEARCH; PRIORITY JOURNAL;

CARDIOVASCULAR DISEASES; HUMANS; LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL; METABOLIC SYNDROME X; PARTICLE SIZE; TRIGLYCERIDES;

EID: 8744253290     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2004.01420.x     Document Type: Note

References (17)

1. Berneis KK, Krauss RM. Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res 2002;43:1363-79.
2. Packard CJ. Triacylglycerol-rich lipoproteins and the generation of small, dense low-density lipoprotein. Biochem Soc Trans 2003;31:1066-9.
3. Krauss RM. Lipids Lipoproteins Patients with Type 2 Diabetes. Diabetes Care 2004;27:1496-504.
4. Anuurad E, Shiwaku K, Enkhmaa B, Nogi A, Kitajima K, Masayuki Y et al. Ethnic difference in the formation of small dense LDL particles in Asians: a comparison of Koreans, Japanese and Mongolians. Eur J Clin Invest 2004;34:738-46.
5. Reaven GM, Chen YD, Jeppesen J, Maheux P, Krauss RM. Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles. J Clin Invest 1993;92:141-6.
6. Lemieux I, Pascot A, Couillard C, Lamarche B, Tchernof A, Alméras N et al. Hypertriglyceridemic waist: a marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein b; small, dense LDL) in men? Circulation 2000;102:179-84.
7. Krauss RM, Siri PW. Metabolic abnormalities: triglyceride and low-density lipoprotein. Endocrinol Metab Clin North Am 2004;33:405-15.
8. Chan DC, Barrert PHR, Warts GF. Dyslipidemia in visceral obesity: mechanisms, implications, and therapy. Am J Cardiovasc Drugs 2004;4:227-46.
9. Ginsberg HN, Huang LS. The insulin resistance syndrome: impact on lipoprotein metabolism and atherothrombosis. J Cardiovasc Risk 2000;7:325-31.
10. Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 1990;82:495-506.
11. Watson TD, Caslake MJ, Freeman DJ, Griffin BA, Hinnie J, Packard CJ et al. Determinants of LDL subfraction distribution and concentrations in young normolipidemic subjects. Arterioscler Thromb Vasc Biol 1994;14:902-10.
12. Bossé Y, Pérusse L, Vohl MC. Genetics of LDL particle heterogeneity: from genetic epidemiology to DNA-based variations. J Lipid Res 2004;45:1008-26.
13. Austin MA, Hokanson JE, Brunzell JD. Characterization of low-density lipoprotein subclasses: methodologic approaches and clinical relevance. Curr Opin Lipidol 1994;5:395-403.
14. Sniderman AD. Applying apoB to the diagnosis and therapy of the atherogenic dyslipoproteinemias: a clinical diagnostic algorithm. Curr Opin Lipidol 2004;15:433-8.
15. Vakkilainen J, Steiner G, Ansquer JC, Aubin F, Rattier S, Foucher C et al. Relationships Between Low-Density Lipoprotein Particle Size, Plasma Lipoproteins, and Progression of Coronary Artery Disease: Diabetes Atherosclerosis Intervention Study (DAIS). Circulation 2003;107:1733-7.
16. Forster LF, Stewart G, Bedford D, Stewart JP, Rogers E, Shepherd J et al. Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates. Atherosclerosis 2002;164:129-45.
17. Cho HK, Shin G, Ryu SK, Jang Y, Day SP, Stewart G et al. Regulation of small dense LDL concentration in Korean and Scottish men and women. Atherosclerosis 2002;164:187-93.